Laboratory findings pre-and post-PBSCT 2 from day +1 to day +13 and engrafted neutrophils on day 11 and platelets on day 30. Serial hematologic findings and immunoglobulin levels were followed after the PBSCT procedure as shown in Table 1 . He did not develop acute or chronic GVHD and is healthy 1 year after PBSCT. Chimerism studies show full donor engraftment ( Figure 1 ). This current report is the first to describe successful allogeneic PBSCT in a WAS patient. Because of the inevitable poor outcome in untreated WAS patients and the lack of any other curative treatment modality, stem cell transplantation should be performed whenever an HLA-identical donor is available. The cost of PBSCT in Thailand is 20 to 30% less than BMT and cord blood stem cell transplantation (CBT) because of the shorter time of transplantation procedure and lack of need for general anesthesia for stem cell collection.
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Multifocal reversible epithelial dysplasia mimicking carcinoma in situ after conditioning therapy with busulfan and cyclophosphamide
Prolonged treatment with alkylating agents may induce changes in both squamous and non-squamous epithelium similar to those seen in spontaneous epithelial dysplasia and carcinoma in situ. 1, 2 We report a patient who developed reversible multifocal epithelial cell changes after conditioning therapy with busulfan and cyclophosphamide followed by autologous peripheral stem cell transplantation for AML.
A 40-year-old woman was diagnosed with acute myeloid leukemia, subtype M5. A total of three induction cycles including two with cytarabine, thioguanine and daunorubicin and one with high-dose cytarabine and mitoxantrone were administered. Complete remission was achieved after the first cycle. Cells for autologous stem cell transplantation were mobilized by a single dose of cyclophosphamide (2500 mg/m 2 ). Conditioning therapy was busulfan (4 mg/kg for 4 days, total of 1250 mg), followed by cyclophosphamide (50 mg/kg for another 4 days, total of 14.4 g). Thereafter, peripheral stem cell transplantation was performed. Acute toxicity observed was WHO grade IV mucositis. As a complication of myelo-ablative therapy hepatic veno-occlusive disease occurred 2 weeks after transplantation and was successfully treated by prostaglandin E1 infusion.
Four months after cessation of chemotherapy, a routine cervical smear revealed severe cytological changes which were interpreted as a high-grade squamous intraepithelial lesion (PAP IVa; CIN III) of the cervix. Consecutively, a cone biopsy and a curettage were performed. Sections of the cone biopsy showed histologic changes consistent with intra-epithelial cervical neoplasia grade III without any evidence of invasion ( Figure  1a, b) . The endometrial mucosa displayed severe atrophic changes with highly atypical features such as enlarged hyperchromatic nuclei.
Further patient work-up revealed multifocal epithelial changes diagnosed by histology and/or cytology. Moderate dysplasia and parakeratosis were demonstrated in a biopsy of the oral mucosa. The gastric and antral mucosa and mucosa of the colon displayed atrophic changes. A biopsy of the duodenal mucosa showed normal epithelium, but irregular nuclear enlargement in Brunner's glands. These changes were classified as mild to moderate dysplasia. Both squamous cells and ciliated cells produced by bronchial alveolar lavage revealed severe dysplastic changes. Biopsy of the bronchus showed atrophic mucosa with severe atypia consistent with carcinoma in situ (Figure 1c, d ). Urothelial cells evaluated by exfoliative urinary cytology displayed changes such as enlarged and irregular nuclei which were regarded as dysplastic.
The diagnosis of a chemotherapy-induced wide-spread epithelial dysplasia was made and the patient was followedup closely.
A control cervical smear 2 months after the cone biopsy showed regression of the cellular atypia with few remaining dyskaryotic cells. Further cytological examinations of cervical, urothelial and bronchial cells revealed no evidence of dysplasia during a follow-up period of 2 years.
The first report of cytologic atypia following chemotherapy was published in 1955. 3 Cytologic changes in different locations varying from a 'polychromatic and polymorphous smear type' 4 to cancer-mimicking alterations 5 have been described in patients after receiving alkylating substances. Changes described were enlargement of cells, marked nuclear enlargement and hyperchromatism.
